Valeant To Allergan: Anything You Can Do I Can Do Better
Executive Summary
The Canadian specialty pharma says its streamlined business model could sufficiently pull costs out of Allergan’s business dealings, including line extensions and post-marketing commitments.
You may also be interested in...
Valeant/Pershing To Allergan: Last Chance To Negotiate
After surprising investors by increasing its bid for Allergan for a second time in one week, Valeant and its activist investor partner Pershing Square, urged management to negotiate before a special meeting is convened to oust the company’s board of directors.
Valeant/Pershing To Allergan: Last Chance To Negotiate
After surprising investors by increasing its bid for Allergan for a second time in one week, Valeant and its activist investor partner Pershing Square, urged management to negotiate before a special meeting is convened to oust the company’s board of directors.
Valeant Clears Decks, Ups Offer For Allergan – And Says B&L Offers Good Blueprint For Integration
Valeant touted the successes of the B&L acquisition in an effort to prove an Allergan integration would be just as seamless. The increased offer to Allergan came on the heels of Valeant selling its dermatological fillers business to Nestle for $1.4 billion, a move that paves the way for integrating Allergan’s similar portfolio.